Literature DB >> 15788656

Associations and interactions between Ets-1 and Ets-2 and coregulatory proteins, SRC-1, AIB1, and NCoR in breast cancer.

Eddie Myers1, Arnold D K Hill, Gabrielle Kelly, Enda W McDermott, Niall J O'Higgins, Yvonne Buggy, Leonie S Young.   

Abstract

PURPOSE: Associations between p160 coactivator proteins and the development of resistance to endocrine treatment have been described. We hypothesized that nuclear receptor coregulatory proteins may interact with nonsteroid receptors. We investigated the mitogen-activated protein kinase-activated transcription factors, Ets, as possible interaction proteins for the coactivators SRC-1 and AIB1 and the corepressor NCoR in human breast cancer. EXPERIMENTAL
DESIGN: Expression and coexpression of Ets and the coregulatory proteins was investigated using immunohistochemistry and immunofluorescence in a cohort of breast tumor patients (N = 134). Protein expression, protein-DNA interactions and protein-protein interactions were assessed using Western blot, electromobility shift, and coimmunoprecipitation analysis, respectively.
RESULTS: Ets-1 and Ets-2 associated with reduced disease-free survival (P < 0.0292, P < 0.0001, respectively), whereas NCoR was a positive prognostic indicator (P < 0.0297). Up-regulation of Ets-1 protein expression in cell cultures derived from patient tumors in the presence of growth factors associated with tumor grade (P < 0.0013; n = 28). In primary breast tumor cell cultures and in the SKBR3 breast cell line, growth factors induced interaction between Ets and their DNA response element, induced recruitment of coactivators to the transcription factor-DNA complex, and up-regulated protein expression of HER2. Ets-1 and Ets-2 interacted with the coregulators under basal conditions, and growth factors up-regulated Ets-2 interaction with SRC-1 and AIB1. Coexpression of Ets-2 and SRC-1 significantly associated with the rate of recurrence and HER expression, compared with patients who expressed Ets-2 but not SRC-1 (P < 0.0001 and P < 0.0001, respectively).
CONCLUSIONS: These data describe associations and interactions between nonsteroid transcription factors and coregulatory proteins in human breast cancer.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15788656     DOI: 10.1158/1078-0432.CCR-04-1192

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  52 in total

1.  Global characterization of the SRC-1 transcriptome identifies ADAM22 as an ER-independent mediator of endocrine-resistant breast cancer.

Authors:  Damian McCartan; Jarlath C Bolger; Aílis Fagan; Christopher Byrne; Yuan Hao; Li Qin; Marie McIlroy; Jianming Xu; Arnold D Hill; Peadar Ó Gaora; Leonie S Young
Journal:  Cancer Res       Date:  2011-11-09       Impact factor: 12.701

Review 2.  Minireview: steroid receptor coactivator-3: a multifarious coregulator in mammary gland metastasis.

Authors:  John P Lydon; Bert W O'Malley
Journal:  Endocrinology       Date:  2010-11-03       Impact factor: 4.736

3.  CSN5 Promotes Hepatocellular Carcinoma Progression by SCARA5 Inhibition Through Suppressing β-Catenin Ubiquitination.

Authors:  Hongliang Liu; Junwen Hu; Hua Pan; Dilai Luo; Mingwen Huang; Wei Xu
Journal:  Dig Dis Sci       Date:  2017-11-30       Impact factor: 3.199

4.  NCOA1 Directly Targets M-CSF1 Expression to Promote Breast Cancer Metastasis.

Authors:  Li Qin; Ye-Lin Wu; Michael J Toneff; Dabing Li; Lan Liao; Xiuhua Gao; Fiona T Bane; Jean C-Y Tien; Yixiang Xu; Zhen Feng; Zhihui Yang; Yan Xu; Sarah M Theissen; Yi Li; Leonie Young; Jianming Xu
Journal:  Cancer Res       Date:  2014-04-25       Impact factor: 12.701

Review 5.  The ETS family of oncogenic transcription factors in solid tumours.

Authors:  Gina M Sizemore; Jason R Pitarresi; Subhasree Balakrishnan; Michael C Ostrowski
Journal:  Nat Rev Cancer       Date:  2017-04-28       Impact factor: 60.716

6.  Genetic ablation of the amplified-in-breast cancer 1 inhibits spontaneous prostate cancer progression in mice.

Authors:  Arthur C-K Chung; Suoling Zhou; Lan Liao; Jean Ching-Yi Tien; Norman M Greenberg; Jianming Xu
Journal:  Cancer Res       Date:  2007-06-15       Impact factor: 12.701

7.  A Pit-1 threonine 220 phosphomimic reduces binding to monomeric DNA sites to inhibit Ras and estrogen stimulation of the prolactin gene promoter.

Authors:  Annie Jean; Arthur Gutierrez-Hartmann; Dawn L Duval
Journal:  Mol Endocrinol       Date:  2009-11-03

8.  Ets2 maintains hTERT gene expression and breast cancer cell proliferation by interacting with c-Myc.

Authors:  Dakang Xu; Julie Dwyer; He Li; Wei Duan; Jun-Ping Liu
Journal:  J Biol Chem       Date:  2008-06-27       Impact factor: 5.157

9.  Ets-1 p51 and p42 isoforms differentially modulate Stromelysin-1 promoter according to induced DNA bend orientation.

Authors:  Gabriel Leprivier; David Baillat; Agnès Begue; Brigitte Hartmann; Marc Aumercier
Journal:  Nucleic Acids Res       Date:  2009-05-21       Impact factor: 16.971

10.  Nuclear receptor co-activators and HER-2/neu are upregulated in breast cancer patients during neo-adjuvant treatment with aromatase inhibitors.

Authors:  M Hauglid Flågeng; L L Haugan Moi; J M Dixon; J Geisler; E A Lien; W R Miller; P E Lønning; G Mellgren
Journal:  Br J Cancer       Date:  2009-09-15       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.